非定型溶血性尿毒症症候群(Atypical Hemolytic Uremic Syndrome)の治療薬パイプライン動向(2015年上半期版)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC6106IDB)
◆英語タイトル:Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2015
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC6106IDB
◆発行日:2015年1月22日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[非定型溶血性尿毒症症候群(Atypical Hemolytic Uremic Syndrome)の治療薬パイプライン動向(2015年上半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における非定型溶血性尿毒症症候群(Atypical Hemolytic Uremic Syndrome)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・非定型溶血性尿毒症症候群(Atypical Hemolytic Uremic Syndrome)の概要
・非定型溶血性尿毒症症候群(Atypical Hemolytic Uremic Syndrome)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・非定型溶血性尿毒症症候群(Atypical Hemolytic Uremic Syndrome)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・非定型溶血性尿毒症症候群(Atypical Hemolytic Uremic Syndrome)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・非定型溶血性尿毒症症候群(Atypical Hemolytic Uremic Syndrome)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Pipeline Review, H1 2015’, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Overview 6
Therapeutics Development 7
Pipeline Products for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Overview 7
Pipeline Products for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Comparative Analysis 8
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Therapeutics under Development by Companies 9
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Products under Development by Companies 12
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Companies Involved in Therapeutics Development 13
Adienne Pharma & Biotech 13
Alnylam Pharmaceuticals, Inc. 14
ChemoCentryx, Inc. 15
Omeros Corporation 16
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ALN-CC5 – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CCX-168 – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ET-006 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ETR-001 – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Mubodina – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
OMS-721 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Recent Pipeline Updates 34
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Dormant Projects 41
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Product Development Milestones 42
Featured News & Press Releases 42
Nov 20, 2014: ChemoCentryx’s CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA 42
Nov 19, 2014: OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients 42
Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies 43
Mar 10, 2014: Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS 44
Mar 04, 2014: Omeros Submits IND to Advance OMS721 Phase 2 Clinical Program 45
Feb 03, 2014: Omeros Announces Positive Data after Completion of Dosing in Phase 1 Clinical Trial with OMS721 47
Dec 18, 2013: FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Complement-Mediated Thrombotic Microangiopathies 47
Jun 20, 2013: Alnylam Scientists Present Preclinical Data With ALN-CC5 For Treatment Of Complement-mediated Diseases 48
Jun 13, 2013: Omeros Obtains Regulatory Approval To Initiate Phase I Clinical Trial For Lead Antibody In MASP-2 Program 50
May 28, 2013: Omeros Files Clinical Trial Application For Lead Antibody In MASP-2 Program 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

[List of Tables]
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), H1 2015 7
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Adienne Pharma & Biotech, H1 2015 13
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 14
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by ChemoCentryx, Inc., H1 2015 15
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Omeros Corporation, H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics - Recent Pipeline Updates, H1 2015 34
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Dormant Projects, H1 2015 41

[List of Figures]
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), H1 2015 7
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Top 10 Targets, H1 2015 18
Number of Products by Stage and Top 10 Targets, H1 2015 19
Number of Products by Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Top 10 Routes of Administration, H1 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23
Number of Products by Top 10 Molecule Types, H1 2015 24
Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

*** 掲載企業 ***

Adienne Pharma & Biotech
Alnylam Pharmaceuticals, Inc.
ChemoCentryx, Inc.
Omeros Corporation

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 世界の電気集じん器市場2015
    The Global Electrostatic Precipitator Industry Report 2015 is a professional and in-depth study on the current state of the Electrostatic Precipitator industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The …
  • 世界及び中国のアミューズメント機器市場2017
    The 'Global and Chinese Amusement Equipment Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Amusement Equipment industry with a focus on the Chinese market. The report provides key statistics on the market status of the Amusement Eq …
  • 世界の産業用ホワイトオイル市場2017
    Industrial White Oil Market Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United St …
  • First Insurance Company (FINS) : 企業概要及びSWOT分析
    This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business. WMI's 'First Insurance Company (FINS) : Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, …
  • ICT予算予測(中規模企業):フィンランド・エネルギー産業部門 – ICT予算内訳予測
    Why was the report written? This report presents the output from Kable’s ICT spend prediction statistical model, a log-linear regression model that provides ICT spending predictions based on a company’s demographic profile. The statistical model has been developed using an extensive collection of su …
  • Texas Mutual Insurance Company – 企業概要
    WMI's 'Texas Mutual Insurance Company - Company Capsule' is a crucial resource for industry executives and anyone looking to access key information about 'Texas Mutual Insurance Company'. WMI's 'Texas Mutual Insurance Company - Company Capsule' report utilizes a wide range of primary and secondary s …
  • 歯磨き粉(Toothpaste)市場(~2017):デンマーク
    Synopsis The report presents detailed data on consumption trends in the Toothpaste category in Denmark, analyzing consumption volumes and values at segment level. It also provides indispensable data on distribution channels along with latest industry news and mergers and acquisitions (of Oral Hygien …
  • 旅客情報システムの世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2022)
    The Passenger Information System, PIS, is the operating tool responsible for providing, at any time, visual and audio information to passengers at stations and transfer facilities, both automatically or programmed manually. Scope of the Report: This report focuses on the Passenger Information System …
  • インテリジェント遠隔端末装置(RTU)の世界市場2017-2021
    About Intelligent RTU RTU is a control device that helps the master device, SCADA, to monitor and communicate with devices in the grid placed in different geographical locations. RTUs can be used in a broad range of electrical and process automation devices wherever SCADA is required to monitor and …
  • スウェーデンの農林業機械市場(Agricultural and Forestry Machinery Market in Sweden)
    This market research report offers a perspective on the actual market situation, trends and future outlook for agricultural and forestry machinery in Sweden. The study provides essential market information for decision-makers including: - Overall market for agricultural and forestry machinery in Swe …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC6106IDB )"非定型溶血性尿毒症症候群(Atypical Hemolytic Uremic Syndrome)の治療薬パイプライン動向(2015年上半期版)" (英文:Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2015)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。